Colon cancer: Preventive agents and the present status of chemoprevention

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 2, 2009, Pages 211-219

  Half, Elizabeth ^a   Arber, Nadir ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Adenoma; Calcium; Chemoprevention; Colorectal cancer; Coxibs; DFMO; HMG CoA reductase inhibitors; Mesalamine; Nonsteroidal anti inflammatory drugs; Sulindac; Vitamin D

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CALCIUM; CALCIUM CARBONATE; CELECOXIB; COLECALCIFEROL; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; EFLORNITHINE; ESTROGEN; GESTAGEN; GLUCONOLACTATE CALCIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESALAZINE; MEVINOLIN; NITRIC OXIDE DONOR; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PRAVASTATIN; PROGESTERONE; ROFECOXIB; SIMVASTATIN; SULINDAC; URSODEOXYCHOLIC ACID; VITAMIN D; ANTINEOPLASTIC AGENT; BILE ACID;

ADENOMATOUS POLYP; CALCIUM INTAKE; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER PREVENTION; CARDIOTOXICITY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLON ADENOMA; COLON CANCER; COLON POLYP; COLON TUMOR; COLORECTAL ADENOMA; COLORECTAL CANCER; COMPETITIVE INHIBITION; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; DIGESTIVE SYSTEM ULCER; DRUG COST; DRUG MEGADOSE; DRUG POTENTIATION; ESTROGEN THERAPY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; INTERNET; LOW DRUG DOSE; MEDLINE; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; ANIMAL; COLORECTAL TUMOR; DRUG COMBINATION; HORMONE SUBSTITUTION;

ADENOMATOUS POLYPS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; BILE ACIDS AND SALTS; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; DRUG THERAPY, COMBINATION; HORMONE REPLACEMENT THERAPY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 65649106947     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560802560153     Document Type: Review

References (87)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71-96
2. Half E, Arber N. Colorectal cancer: an update for diagnosis and prevention. Pract Gastroenterol 2007;31(10):20-35
3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61(5):759-767 (Pubitemid 20185636)
4. Grady WM. Genetic testing for high-risk colon cancer patients. Gastroenterology 2003;124(6):1574-1594 (Pubitemid 36617678)
5. Arber N, Levin B. Chemoprevention of colorectal neoplasia: the potential for personalized medicine. Gastroenterology 2008;134(4):1224-1237
6. Ahnen DJ. Colon cancer prevention by NSAIDs: what is the mechanism of action? Eur J Surg Suppl 1998;582:111-114
7. Arber N. Do NSAIDs prevent colorectal cancer? Can J Gastroenterol 2000;14(4):299-307
8. Rao CV, Rivenson A, Simi B, et al. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 1995;55(7):1464-1472
9. Rao CV, Reddy BS. NSAIDs and chemoprevention. Curr Cancer Drug Targets 2004;4(1):29-42 (Pubitemid 38332562)
10. Oshima M, Murai N, Kargman S, et al. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001;61(4):1733-1740
11. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998;58(3):409-412
12. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983;24(1):83-87
13. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988;48(15):4399-4404 (Pubitemid 18181726)
14. Thun MJ, Namboodiri MM, Heath CW, Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325(23):1593-1596
15. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333(10):609-614
16. Giovannucci E, Rimm EB, Stampfer MJ, et al. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994;121(4):241-246
17. Loren DE, Lewis J, Kochman ML. Colon cancer: detection and prevention. Gastroenterol Clin North Am 2002;31(2):565-586 (Pubitemid 34761227)
18. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-899 (Pubitemid 36297997)
19. Benamouzig R, Deyra J, Martin A, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial 1. Gastroenterology 2003;125:328-336 (Pubitemid 36929412)
20. Logan RF, Grainge MJ, Shepherd VC, et al. ukCAP Trial Group. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 2008;134(1):29-38
21. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-890 (Pubitemid 36297996)
22. Leshno M, Moshkowitz M, Arber N. PRO: aspirin is clinically effective in chemoprevention of colorectal neoplasia. Cancer Epidemiol Biomarkers Prev 2008;17(7) 1553-1561
23. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-1899 (Pubitemid 29272670)
24. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2(COX-2). Cell 1996;87(5):803-809 (Pubitemid 26404280)
25. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107(4):1183-1188 (Pubitemid 24294584)
26. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342(26):1946-52 • This paper proved for the first time that celecoxib is effective in reducing adenoma burden in FAP.
27. Baron JA, Sandler RS, Bresalier RS, et al. and APPROVe Trial Investigators, a randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006;131(6):1674-82 • This paper was the first to find that treatment with rofecoxib caused a reduction in polyp recurrence rate among subjects with history of sporadic adenomas.
28. Bertagnolli MM, Eagle CJ, Zauber AG, et al. and APC Study Investigators. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84 • This study, together with reference [29], was the first to show reduction in adenoma recurrence among subjects with history of a sporadic adenoma treated with celecoxib.
29. Arber N, Eagle C, Spicak J, et al. A randomized controlled trial of celecoxib for prevention of colorectal sporadic adenomatous polyps (PreSAP). N Engl J Med 2006;355:885-95 • This study, together with reference [28], was the first to show reduction in adenoma recurrence among subjects with history of a sporadic adenoma treated with celecoxib.
30. Arber N, Spicak J, Racz I, et al. Detection of polyps in adenoma-prone patients two years after celecoxib discontinuation: findings in the PreSAP follow-up. Gastroenterology 2008;(submitted)
31. Bertagnolli MM, Eagle C, Zauber A, et al. The Adenoma Prevention with Celecoxib (APC) trial:5-year efficacy and safety results. Cancer Prev Res 2008
32. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352(11):1092-102 • This study illustrated for the first time that rofecoxib may cause excess cardiovascular events.
33. Solomon SD, Mc Murray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352(11):1071-1080 (Pubitemid 40365348)
34. Solomon SD, Pfeffer JJ, Mc Murray, et al. and APC and PreSAP Trial Investigators. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006;114:1028-1035
35. Tuma R. Drugs to prevent colon cancer show promise, but hurdles remain for chemoprevention. J Natl Cancer Inst 2008;100(11):764-766
36. Wallace JL, Del Soldato P. The therapeutic potential of NO-NSAIDs. Fundam Clin Pharmacol 2003;17(1):11-20 (Pubitemid 36241449)
37. Mizoguchi H, Hase S, Tanaka A, Takeuchi K. Lack of small intestinal ulcerogenecity of nitric oxide-releasing indomethacin, NCX-530, in rats. Aliment Pharmacol Ther 2001;15(2):257-267 (Pubitemid 32142505)
38. Rigas B, Kashfi K. Nitric-oxide-donating NSAIDs as agents for cancer prevention. Trends Mol Med 2004;10(7):324-330 (Pubitemid 38881521)
39. Velazquez C, Praveen Rao PN, Knaus EE. Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: design, synthesis, biological evaluation, and nitric oxide release studies. J Med Chem 2005;48(12):4061-4067 (Pubitemid 40800614)
40. Bak AW, Mc Knight W, Li P, et al. Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma. Life Sci 1998;62(23):367-373 (Pubitemid 28239732)
41. Rao CV, Reddy BS, Steele VE, et al. Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol Cancer Ther 2006;5(6):1530-1538 (Pubitemid 44070490)
42. Williams JL, Kashfi K, Ouyang N, et al. NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/+)) mice. Biochem Biophys Res Commun 2004;313(3):784-788 (Pubitemid 38021899)
43. Rao CV, Newmark HL, Reddy BS. Chemopreventive effect of farnesol and lanosterol on colon carcinogenesis. Cancer Detect Prev 2002;26(6):419 (Pubitemid 36035371)
44. Swamy MV, Cooma I, Reddy BS, et al. caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: a novel approach in developing effective chemopreventive regimens. Int J Oncol 2002;20(4):753-759
45. Agarwal B, Rao CV, Bhendwal S, et al. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 1999;117(4):838-847 (Pubitemid 29468226)
46. Narisawa T, Fukaura Y, Terada K, et al. Prevention of 1,2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice. Carcinogenesis 1994;15(9):2045-2048 (Pubitemid 24303058)
47. Swamy MV, Patlolla JM, Steele VE, et al. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APC Min mice. Cancer Res 2006;66(14):7370- 7377 (Pubitemid 44197721)
48. Pedersen TR, Berg K, Cook TJ, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1996;156(18):2085-2092 (Pubitemid 26346967)
49. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335(14):1001-1009
50. Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005;352(21):2184-2192 (Pubitemid 40727085)
51. Brentnall TA. Ursodiol: good drug makes good. Gastroenterology 2003;124(4):1139-1140 (Pubitemid 36389812)
52. Alberts DS, Martínez ME, Hess LM. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst 2005;97(11):846-853 (Pubitemid 40909127)
53. Luk GD, Baylin SB. Ornithine decarboxylase as a biologic marker in familial colonic polyposis. N Engl J Med 1984;311(2):80-83 (Pubitemid 14084078)
54. Rozhin J, Wilson PS, Bull AW, Nigro ND. Ornithine decarboxylase activity in the rat and human colon. Cancer Res 1984;44(8):3226-3230 (Pubitemid 14098560)
55. Hixson LJ, Garewal HS, Mc Gee DL, et al. Ornithine decarboxylase and polyamines in colorectal neoplasia and mucosa. Cancer Epidemiol Biomarkers Prev 1993;2(4):369-374
56. Meyskens FL, Jr, Gerner EW, Emerson S, et al. Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention. J Natl Cancer Inst 1998;90(16):1212-1218 (Pubitemid 28407087)
57. Janne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med 2000;342(26):1960-1968 (Pubitemid 30419092)
58. Giovannucci E. Modifiable risk factors for colon cancer. Gastroenterol Clin North Am 2002;31(4):925-943
59. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50(1):7-33
60. Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW, Jr. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 1995;87(7):517-523
61. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288(3):321-333 (Pubitemid 34761611)
62. Velayos FS, Loftus EJ, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 2006;130:1941-1949 (Pubitemid 43816957)
63. Moody GA, Jayanthi V, Probert CS, et al. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996;8:1179-1183 (Pubitemid 26413548)
64. Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000;14:145-153 (Pubitemid 30088290)
65. Rubin DT, Lo Savio A, Yadron N, et al. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol 2006;4:1346-1350 (Pubitemid 44716744)
66. Jess T, Loftus EJ, Velayos FS, et al. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen County, Denmark and Olmsted County, Minnesota. Am J Gastroenterol 2007;102:829-836 (Pubitemid 46496613)
67. Terdiman JP, Steinbuch M, Blumentals WA, et al. 5-aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis 2007;13:367-371 (Pubitemid 46668239)
68. Schmiegel W, Pox CP, Reiser M. German 5-ASA Polyp Prevention Study Group (GAPPS). Effect of 5-aminosalicylate (5-ASA) on the recurrence rate of sporadic colorectal adenomas [abstract]. Gastroenterology 2004;126(Suppl 2):A-452
69. Shpitz B, Giladi N, Sagiv E, et al. Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model. Digestion 2006;74(3-4):140-144 (Pubitemid 46622782)
70. Baron JA, Beach M, Mandel JS, et al. and Calcium Polyp Prevention Study Group. Calcium supplements for the prevention of colorectal adenoma. N Engl J Med 1999;340:101-107
71. Bonithon-Kopp O, Kronborg A, Giacosa, et al. and European Cancer Prevention Organization Study Group. Calcium and fiber supplementation in prevention of colorectal adenoma recurrence: a randomized intervention trial. Lancet 2000;365:1300-1306
72. Martinez ME, Giovannucci EL, Colditz GA, et al. Calcium, vitamin D, and the occurrence of CRC among women. J Natl Cancer Inst 1996;88(19):1375-1382 (Pubitemid 26329755)
73. Wu K, Willett WC, Fuchs CS, et al. Calcium intake and risk of colon cancer in women and men. J Natl Cancer Inst 2002;94:437-446 (Pubitemid 34285093)
74. Kearney J, Giovannucci E, Rimm EB, et al. Calcium, vitamin D, and dairy foods and the occurrence of colon cancer in men. Am J Epidemiol 1996;143(9):907-917 (Pubitemid 26131098)
75. Bostick RM, Potter JD, Sellers TA, et al. Relation of calcium, vitamin D, and dairy food intake to incidence of colon cancer among older women. The Iowa Women's Health Study. Am J Epidemiol 1993;137(12):1302-1317 (Pubitemid 23215031)
76. McCullough ML, Robertson AS, Rodriguez C, et al. Calcium, vitamin D, dairy products, and risk of CRC in the Cancer Prevention Study II Nutrition. Cancer Causes Control 2003;14(1):1-12
77. La Vecchia C, Braga C, Negri E, et al. Intake of selected micronutrients and risk of colorectal cancer. Int J Cancer 1997;73:525-530 Cohort (United States) (Pubitemid 28005316)
78. Marcus PM, Newcomb PA. The association of calcium and vitamin D, and colon and rectal cancer in Wisconsin women. Int J Epidemiol 1998;27(5):788-793 (Pubitemid 28504965)
79. Terry P, Baron JA, Bergkvist L, et al. Dietary calcium-vitamin D intake and risk of colorectal cancer: a prospective cohort study in women. Nutr Cancer 2002;43:39-46 (Pubitemid 35387254)
80. Kesse E, Boutron-Ruault MC, Norat T, et al. Dietary calcium, phosphorus, vitamin D, dairy products and the risk of colorectal adenoma among French women of the E3N-EPIC prospective study. Int J Cancer 2005;117:137-144 (Pubitemid 41262767)
81. Reddy BS, Wang CX, Kong AN, et al. Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res 2006;66(8):4542-4546
82. Jacoby RF, Cole CE, Tutsch K, et al. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res 2000;60(7):1864-1870 (Pubitemid 30207645)
83. Jacoby RF, Cole CE, Hawk ET, Lubet RA. Ursodeoxycholate/sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis. Gastroenterology 2004;127(3):838-844 (Pubitemid 39208416)
84. Meyskens FL, Jr, Mc Laren CE, Daniel Pelot D, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res 2008;1:32-8 • This study found that combination treatment with a nonselective COX inhibitor and DFMO was effective in reducing adenoma recurrence in patients with history of sporadic adenomas with minimal side effects.
85. Suleiman S, Rex DK, Sonnenberg A. Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis. Gastroenterology 2002;122(1):78-84 (Pubitemid 34049197)
86. Ladabaum U, Chopra CL, Huang G, et al. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis. Ann Intern Med 2001;135(9):769-781
87. Ladabaum U, Scheiman JM, Fendrick AM. Potential effect of cyclooxygenase-2-specific inhibitors on the prevention of colorectal cancer: a cost-effectiveness analysis. Am J Med 2003;114(7):546-554 (Pubitemid 36577257)